CN103622981A - Compound glycyrrhizin oral liquid and preparation method thereof - Google Patents

Compound glycyrrhizin oral liquid and preparation method thereof Download PDF

Info

Publication number
CN103622981A
CN103622981A CN201210309241.5A CN201210309241A CN103622981A CN 103622981 A CN103622981 A CN 103622981A CN 201210309241 A CN201210309241 A CN 201210309241A CN 103622981 A CN103622981 A CN 103622981A
Authority
CN
China
Prior art keywords
agent
weight
acid
snmc
essence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201210309241.5A
Other languages
Chinese (zh)
Inventor
王世岭
李孟广
张超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEILONGJIANG BAITONG CHILDREN'S MEDICINES RESEARCH CO., LTD.
Original Assignee
Kang Yangrun And (beijing) Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kang Yangrun And (beijing) Medical Technology Co Ltd filed Critical Kang Yangrun And (beijing) Medical Technology Co Ltd
Priority to CN201210309241.5A priority Critical patent/CN103622981A/en
Publication of CN103622981A publication Critical patent/CN103622981A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a compound glycyrrhizin oral liquid and a preparation method thereof against the physiologic characteristics and clinic treatment demands of special populations. The above oral liquid is prepared by using glycyrrhizin, cysteine hydrochloride, glycine and a pharmaceutic adjuvant, wherein a weight ratio of glycyrrhizin to cysteine hydrochloride to glycine is 1:1:1, and the pharmaceutic adjuvant is selected from one or more of a sweetener, a flavoring, an antiseptic, a pH adjusting agent, plant oil, an emulsifier, a diluent, a disintegrating agent and an adhesive.

Description

SNMC oral liquid and preparation method thereof
Technical field:
The present invention relates to medical technical field, relate to particularly oral liquid of being made by glycyrrhizic glycoside, cysteine, glycine and pharmaceutic adjuvant and preparation method thereof.Be applied to the control of the diseases such as hepatopathy field, dermatosis field, tumor chemoradiotherapy protection field.
Background technology:
Compound glycyrrbizic acid glycosides formulation was produced and is appeared on the market in Japan in 1948 the earliest, at first for treating skin disease.1958, Japanese doctor helped Yamamoto husband and attempts with it, treating chronic hepatitis, result patient's liver function index BSP(bromine sulfonephthalein) value obtained obvious improvement.Within 1977, the grand professor of Japanese hepatopathy expert's Suzuki adopts strict randomized controlled method to verify the therapeutical effect of SNMC to chronic hepatitis, has confirmed that it is to chronic hepatitis determined curative effect; After this, SNMC has been subject to the attention of height as the medicine of hepatitis, and basis and clinical research are more deep, and range of application and clinical indication progressively expand.Bears Tian Boguang in 2002 has reported that again SNMC is to the challenging late result result of hepatitis C, and has obtained the pathological checking support of hepatopathy.Within 1985, start said preparation and introduce China's treatment chronic viral hepatitis, not only can significantly improve chronic hepatitis patient's liver function, reduce aminotransferase, and can control chronic hepatitis to the development process of liver cirrhosis, hepatocarcinoma.Therefore, SNMC obtains rapidly numerous medical personnel's approval with its unique efficacy and saferry.Over more than 20 years; a large amount of bases and clinical research data show; said preparation has antiinflammatory, immunomodulating, to the inhibition of experimental hepatocyte injury, virus replication with to viral deactivation, antiallergic action and the effect of parahormone sample etc.; be widely used in the control of the diseases such as hepatopathy field, dermatosis field, tumor chemoradiotherapy protection field; and untoward reaction is few, there are good compliance and safety.
Chronic hepatitis B, in one of the commonly encountered diseases of Chinese sickness rate Hen Gao,Shi China, frequently-occurring disease, is to threaten the maximum killer of national health.Chronic hepatitis B has an appointment 1/10th in crowd according to estimates, and 1.2 hundred million, the person that is hepatitis b surface antigen positive; Wherein approximately 1/4th, 3,000 ten thousand is Chronic Hepatitis B.According to relevant data statistics, show, suffer from the patient of chronic viral hepatitis B disease, teen-age ratio is many especially, more than 95% is to infect before 3 years old, and this allows a lot of hepatopathy experts and teenager all feel relatively to perplex.These patients due to infect viral hepatocellular removing not exclusively, not thorough, generation new life is repeatedly hepatocellular to be infected again, make hepatocyte repeatedly destroy and regenerate, there is the change of liver structure and the hypertrophy of fibrous tissue thereupon, after the hepatitis activity several years, approximately 1/3 patient there will be liver cirrhosis, ascites, and even hepatocarcinoma.
Glycyrrhizic glycoside, claim again glycyrrhizic acid (Glycyrrhizicacid, GA), glycyrrhizin (Glycyrrhizin, GL), chemistry 3-O-(2 '-beta d glucopyranosiduronic acid base)-beta d glucopyranosiduronic acid glycosides 3 beta-hydroxies-11-carbonyl oxygen-18 β oleanolic acid-12-alkene-30-carboxylic acid by name, English chemical name: 3-O-(2 '-β-D-glucuronopyranosyl)-β-D-glucuronopyranoside3 β-hydroxy-11-oxo-18-olean-12-en-30-oic acid is the effective ingredient of separation and Extraction from Radix Glycyrrhizae.At present, SNMC has been widely used in clinical as the standard care medicine of chronic hepatitis in Japan, thereby stop and delay hepatitis B diseases, proceed to liver cirrhosis, hepatocarcinoma.Yet, SNMC oral glycyrrhizic glycoside preparation in clinical practice only has tablet at present, the solid preparations such as capsule, for example CN200610045278.6 patent documentation discloses a kind of solid soft capsule being prepared from by glycyrrhizic glycoside and glycine and methionine and excipient substance, CN200710151969.9 discloses a kind of by glycyrrhizic glycoside and methionine, the glycyrrhizin dropping pills preparation that glycine and Basic compose are made, CN20111084341.5 discloses a kind of by glycyrrhizic glycoside and methionine or add glycine again, aqueous injection prepared by cysteine hydrochloride, injectable powder or infusion preparation.
Yet in existing above-mentioned preparation, there are the following problems for solid orally ingestible: (1) old man and children's are not easy to accept, the inconvenience of taking medicine, and pediatric pharmaceuticals should be by age or body weight within different minutes, measure administration, and solid preparation old man and child administration difficulty, the bad accurate grasp of medication metering; (2) some are swallowed the inconvenient patient of solid drugs (as elderly and infirm) medication and have any problem; (3) the oral rear dissolution time of solid drugs is longer, absorbs slowlyer, and drug effect effect not in time.That is, as the drop pill of peroral dosage form, capsule its to leach speed lower, onset is slow, bioavailability is low, especially for child patient, takes very inconveniently, and needs divided dose to cause over administration or by quantity not sufficient; Although and that injection leaches speed is fast, bioavailability is high, its medication very inconvenient (needing hospitalization) is low for the non-hospitalization compliance of especial patient, and particularly children chronic hepatitis is difficult to adhere to injecting drug use.It is the task of top priority that dosage form and the specification of applicable child, old man, patient bedridden in long term and its physiological characteristics of dysphagia patients are provided, and is also the important measures that guarantee such crowd's rational use of drug.But glycyrrhizic glycoside is unstable in solution, easily produce precipitation and effective ingredient and degraded occurs and lower drug effect, therefore, have not yet to see the report of glycyrrhizic glycoside liquid oral medicine.
Summary of the invention:
For solving the above-mentioned problems in the prior art, the inventor is through long-term deep research, be surprisingly found out that, with etc. glycyrrhizic glycoside, cysteine and the glycine of weight ratio can make stable glycyrrhizic glycoside liquid oral medicine, said preparation has good stability, meet clinical application requirement completely, thereby completed the present invention.Therefore, the present invention is directed to physiological characteristics and the clinical treatment demand of special population, a kind of SNMC oral liquid and preparation method thereof is provided.The present invention is to be main component by glycyrrhizic glycoside, cysteine, glycine, and three's weight ratio is 1:1:1, and adds the SNMC oral liquid that pharmaceutic adjuvant is made.Liquid preparation of the present invention refers to (but being not limited to) oral administration solution, syrup, Orally taken emulsion, or faces the used time and add the liquid preparation (dry syrup, granule etc.) that mixing in water for oral taking (dissolving) forms.Glycyrrhizic glycoside, cysteine and glycine in described preparation content all in 0.05~10% weight range (preferably 0.5%-5% weight), and glycyrrhizic glycoside: cysteine: glycine=1:1:1(weight).
According to SNMC oral liquid of the present invention, it is characterized in that, described pharmaceutic adjuvant is one or more in the sweeting agent that contains 1~80 % by weight or the correctives that contains 0.01~10 % by weight or the antiseptic that contains 0.01~10 % by weight or the pH adjusting agent that contains 0.01~10 % by weight or vegetable oil, emulsifying agent, diluent, disintegrating agent and binding agent.
Wherein pharmaceutic adjuvant comprises sweeting agent, correctives, antiseptic, pH adjusting agent, vegetable oil, emulsifying agent, diluent, disintegrating agent and binding agent etc.
Above-mentioned sweeting agent is one or more in sucrose, cyclamate, stevioside, fructose, glucose, simple syrup, aspartame, protein sugar, saccharin sodium, maltose alcohol, sorbitol;
Above-mentioned correctives is one or more in Mentholum, flavoring banana essence, Fructus Citri tangerinae essence, flavoring pineapple essence, Fructus Citri Limoniae essence, strawberry essence, rose essence, cherry essence, Oleum Cinnamomi, orange peel oil, milk-taste essence, chocolate essence, powder cocoanut flavour;
Foregoing preservatives is one or more in nipagin, aethyl parabenum, propylparaben, oxybenzene butyl formate, sorbic acid, potassium sorbate, calcium sorbate, benzoic acid, sodium benzoate;
Above-mentioned pH adjusting agent is one or more in dilute hydrochloric acid, lactic acid, malic acid, citric acid, phosphoric acid, acetic acid, succinic acid, propanoic acid;
Above-mentioned vegetable oil is one or more in soybean oil, Oleum Arachidis hypogaeae semen, olive oil;
Mentioned emulsifier is one or more in non-ionic surface emulsifying agent, the agent of anion ratio surfactant emulsion, or the compound emulsifying agent forming in proportion, as female in phospholipid-pool Lip river sand etc.;
Above-mentioned diluent is one or more in starch, lactose, cane sugar powder etc.;
Above-mentioned disintegrating agent and binding agent are starch, cellulose derivative, hypromellose (HPMC), ethyl cellulose (EC), IV acrylic resin (Eudragit IV), polyvinyl alcohol (PVA), pluronic gram F 68(Pluronic F 68), polyethylene glycol 6000 (PEG 6000), one or more in low-substituted hydroxypropyl methylcellulose (L-HPC).
As follows according to the concrete preparation method of SNMC oral liquid of the present invention:
1. oral administration solution glycyrrhizic glycoside, cysteine, glycine are main component, add pharmaceutic adjuvant and make.Wherein pharmaceutic adjuvant comprises sweeting agent, correctives, pH adjusting agent and antiseptic etc.According to oral solution preparation rules, prepare and get final product.
2. syrup glycyrrhizic glycoside, cysteine, glycine are main component, add pharmaceutic adjuvant and make.Wherein pharmaceutic adjuvant comprises sucrose, sweeting agent, correctives, pH adjusting agent and antiseptic etc.According to syrup preparation rules, prepare and get final product.
3. Orally taken emulsion glycyrrhizic glycoside, cysteine, glycine are main component, add pharmaceutic adjuvant and make stable oil/water type emulsion for oral liquid preparation.Conventional solvent is water and vegetable oil, and after emulsifying agent emulsifying, the drop that particle diameter is mostly more than 0.1 μ m is dispersed in the liquid preparation that forms the oral oil/water type emulsion of confession in liquid dispersion medium.In Orally taken emulsion, can add suitable emulsifying agent, coemulsifier, suspending agent.Also add suitable antiseptic, correctives, antioxidant etc., mainly by dispersion method, prepare.Can adopt dispersing emulsification machine, colloid mill, the preparation of ultrasonic emulsification device.
4. dry syrup glycyrrhizic glycoside, cysteine, glycine are main component, add pharmaceutic adjuvant and make.In dry syrup, adjuvant used comprises hypromellose (HPMC), ethyl cellulose (EC), IV acrylic resin (Eudragit IV), polyvinyl alcohol (PVA), pluronic gram F 68(Pluronic F 68), polyethylene glycol 6000 (PEG 6000), low-substituted hydroxypropyl methylcellulose (L-HPC), sucrose, mannitol, glucose, ethyl hydroxybenzoate, powder cocoanut flavour.PEG 6000as binding agent, and in prescription, add cellulose family and the less water-soluble saccharides adjuvant of hygroscopicity with HPMC.
5. granule glycyrrhizic glycoside, cysteine, glycine are main component, add pharmaceutic adjuvant and make.Icing Sugar, dextrin are as major auxiliary burden.By medicine and diluent (as starch, lactose, sucrose etc.), also can add if desired disintegrating agent (as starch, cellulose derivative etc.), correctives, fully mix, add appropriate water or other binding agents to mix soft material processed, mix available various types of mixer and carry out.Granulate (can adopt dry granulation, wet granulation, sulfuration spray granulation, spray-drying process), dry, granulate, packing, obtains.
SNMC oral liquid of the present invention, has increased the peroral dosage form of SNMC, has realized again SNMC and has directly entered in body with liquid form, taking convenience, absorbs soon, and onset is rapid, the object that bioavailability is high; Compare with injection and overcome injection and use and carry inconvenient shortcoming.In addition safe, patient compliance good, the patient who is particularly suitable for child, old people and dysphagia takes, this is that other dosage forms are incomparable.While preparation method of the present invention, technique is simple, is suitable for suitability for industrialized production.、
The specific embodiment:
By embodiment, enter a cloth and illustrate the present invention, but embodiment does not constitute any limitation the present invention.All technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1. SNMC oral administration solutions
Prescription forms: glycyrrhizic glycoside 5g, cysteine hydrochloride 5g, glycine 5g, stevioside 0.5g, essence 1g, benzoic acid 2g, citric acid are appropriate, and water adds to 1000ml.
Preparation method:
Glycyrrhizic glycoside, cysteine hydrochloride, glycine, stevioside are added in suitable quantity of water and dissolved respectively; After separately benzoic acid and essence being dissolved respectively, join in medicinal liquid, stir evenly; With citric acid soln, regulate pH value, add purified water to enough, stir evenly, filter, subpackage, sterilizing, obtains.
Embodiment 2. SNMC syrup
Prescription forms: glycyrrhizic glycoside 10g, cysteine hydrochloride 10g, glycine 10g, sucrose 450g, Fructus Citri tangerinae essence 2g, aethyl parabenum 1g, malic acid are appropriate, water adds to 1000ml.
Preparation method: glycyrrhizic glycoside, cysteine hydrochloride, glycine, sucrose are added in suitable quantity of water and dissolved respectively; Separately aethyl parabenum is added to dissolve with ethanol, after Fructus Citri tangerinae essence is dissolved in water, join respectively in medicinal liquid, stir evenly; Malic acid is added after suitable quantity of water is dissolved and regulates pH value, add purified water to enough, stir evenly, filter, subpackage, sterilizing, obtains.
Embodiment 3. SNMC Orally taken emulsions
Prescription forms: glycyrrhizic glycoside 25g, cysteine hydrochloride 25g, glycine 25g, soybean oil 440g, stevioside 0.3g, emulsifying agent [phospholipid-pool Lip river husky female (1:6)] 7.0g, benzoic acid 1.5g, citric acid are in right amount, water adds to 1000ml.
Preparation method: adopt Mechanical Method preparation.Glycyrrhizic glycoside, cysteine hydrochloride, glycine, stevioside, benzoic acid, citric acid etc. are added after appropriate amount of purified water dissolving, add soybean oil, emulsifying agent (phospholipid-pool Lip river is husky female), through high speed dispersing emulsification machine machine, stir (10000 r/ min) 1 5min, add water to enough, stir again, subpackage, sterilizing, obtains.
Embodiment 4. SNMC dry syrups
Prescription forms: glycyrrhizic glycoside 15g, cysteine 15g, glycine 15g, HPMC 60g, binding agent (PEG 6000, HPMC) appropriate, sucrose is appropriate, ethyl hydroxybenzoate is appropriate, powder cocoanut flavour is appropriate, makes altogether 1000g.
Preparation method: take each component by recipe quantity, cross respectively 100 mesh sieves, ethyl hydroxybenzoate is adsorbed in carbohydrate admixture after with a little anhydrous alcohol solution, and principal agent, hypromellose and essence fully mix, by equivalent incremental method and saccharide adjuvant, fully mix, add by PEG 6000granulate with the binding agent that HPMC forms.Dry, granulate, subpackage, obtains.
Embodiment 5. SNMC granules
Prescription forms: glycyrrhizic glycoside 20g, Cys2 0g, glycine 20g, cane sugar powder 80g, starch is appropriate, dextrin is appropriate, powder cocoanut flavour appropriate, disintegrating agent (cellulose derivative etc.) in right amount, benzoic acid 2g, make altogether 1000g.
Preparation method: take each component by recipe quantity, cross respectively 100 mesh sieves, soft material processed, granulates (can adopt dry granulation, wet granulation, sulfuration spray granulation, spray-drying process), dry, granulate, packing, obtains.

Claims (7)

1. a SNMC oral liquid, said preparation is made by glycyrrhizic glycoside, cysteine hydrochloride, glycine and pharmaceutic adjuvant, wherein the weight ratio of glycyrrhizic glycoside, cysteine hydrochloride, glycine is 1:1:1, and pharmaceutic adjuvant is selected from one or more in sweeting agent, correctives, antiseptic, pH adjusting agent, vegetable oil, emulsifying agent, diluent, disintegrating agent and binding agent.
2. according to the SNMC oral liquid of claim 1, it is oral administration solution, syrup, Orally taken emulsion, or faces the used time and add mixing in water for oral taking and dissolve liquid preparation such as the dry syrup form, granule etc.
3. according to the SNMC oral liquid described in claim 1-2, it is characterized in that the glycyrrhizic glycoside that contains 0.05~10 % by weight in described preparation; The cysteine of 0.05~10 % by weight; The glycine of 0.05~10 % by weight.
4. according to the SNMC oral liquid described in claim 1-2, it is characterized in that the glycyrrhizic glycoside that contains 0.5~5 % by weight in described preparation; The cysteine of 0.5~5 % by weight; The glycine of 0.5~5 % by weight.
5. according to the SNMC oral liquid described in claim 1-2, it is characterized in that, described pharmaceutic adjuvant is one or more in the sweeting agent that contains 1~80 % by weight or the correctives that contains 0.01~10 % by weight or the antiseptic that contains 0.01~10 % by weight or the pH adjusting agent that contains 0.01~10 % by weight or vegetable oil, emulsifying agent, diluent, disintegrating agent and binding agent.
6. the SNMC oral liquid as described in claim 1-2, it is characterized in that, described sweeting agent is one or more in sucrose, cyclamate, stevioside, fructose, simple syrup, aspartame, protein sugar, saccharin sodium, maltose alcohol, sorbitol; Correctives is one or more in Mentholum, flavoring banana essence, Fructus Citri tangerinae essence, flavoring pineapple essence, Fructus Citri Limoniae essence, strawberry essence, rose essence, cherry essence, Oleum Cinnamomi, orange peel oil, chocolate essence; Antiseptic is one or more in nipagin, aethyl parabenum, propylparaben, oxybenzene butyl formate, sorbic acid, potassium sorbate, calcium sorbate, benzoic acid, sodium benzoate; PH adjusting agent is one or more in dilute hydrochloric acid, lactic acid, malic acid, citric acid, phosphoric acid, acetic acid, succinic acid, propanoic acid; Vegetable oil is one or more in soybean oil, Oleum Arachidis hypogaeae semen, olive oil; Emulsifying agent is one or more in non-ionic surface emulsifying agent, the agent of anion ratio surfactant emulsion, or the compound emulsifying agent forming in proportion; Diluent is one or more in starch, lactose, cane sugar powder etc.; Disintegrating agent and binding agent are starch, cellulose derivative, hypromellose, ethyl cellulose, IV acrylic resin, polyvinyl alcohol, pluronic gram F 68, one or more in polyethylene glycol 6000, low-substituted hydroxypropyl methylcellulose.
7. SNMC oral liquid as claimed in claim 6, wherein compound emulsifying agent is the husky female compound emulsifying agent in phospholipid-pool Lip river.
CN201210309241.5A 2012-08-27 2012-08-27 Compound glycyrrhizin oral liquid and preparation method thereof Pending CN103622981A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210309241.5A CN103622981A (en) 2012-08-27 2012-08-27 Compound glycyrrhizin oral liquid and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210309241.5A CN103622981A (en) 2012-08-27 2012-08-27 Compound glycyrrhizin oral liquid and preparation method thereof

Publications (1)

Publication Number Publication Date
CN103622981A true CN103622981A (en) 2014-03-12

Family

ID=50204668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210309241.5A Pending CN103622981A (en) 2012-08-27 2012-08-27 Compound glycyrrhizin oral liquid and preparation method thereof

Country Status (1)

Country Link
CN (1) CN103622981A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203499A1 (en) 2015-06-19 2016-12-22 Chigurupati Harsha Synergistic beverage composition
CN108938562A (en) * 2017-05-25 2018-12-07 北京万全德众医药生物技术有限公司 Choline Glycerophosphate oral solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101317852A (en) * 2008-06-27 2008-12-10 北京京卫信康医药科技发展有限公司 Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof
CN101766641A (en) * 2010-01-20 2010-07-07 北京凯因科技股份有限公司 Compound glycyrrhizin injection preparation
CN102302502A (en) * 2011-06-30 2012-01-04 北京秦武田制药有限公司 Compound glycyrrhizin preparation and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101317852A (en) * 2008-06-27 2008-12-10 北京京卫信康医药科技发展有限公司 Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof
CN101766641A (en) * 2010-01-20 2010-07-07 北京凯因科技股份有限公司 Compound glycyrrhizin injection preparation
CN102302502A (en) * 2011-06-30 2012-01-04 北京秦武田制药有限公司 Compound glycyrrhizin preparation and preparation method thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203499A1 (en) 2015-06-19 2016-12-22 Chigurupati Harsha Synergistic beverage composition
CN107920577A (en) * 2015-06-19 2018-04-17 哈沙·奇古鲁帕蒂 Cooperate with beverage composition for treating dental erosion
US10456359B2 (en) 2015-06-19 2019-10-29 Harsha Chigurupati Synergistic beverage composition
CN108938562A (en) * 2017-05-25 2018-12-07 北京万全德众医药生物技术有限公司 Choline Glycerophosphate oral solution

Similar Documents

Publication Publication Date Title
CN104587260B (en) The composition of bamboo-leaves flavones and chitosan oligosaccharide, its preparation method and application
WO2002030400A1 (en) Solid preparations
CN101185733A (en) Jianweixiaoshi orally disintegrating tablets and preparation method
CN109662949B (en) Fluorohydrocortisone acetate orally disintegrating tablet and preparation method thereof
CN101352417A (en) Ambroxol hydrochloride oral solution and preparation method thereof
CN107714642A (en) A kind of oral solution of EV71 viruses and CVA16 viral inhibitors and preparation method thereof
CN103622951B (en) Lian Bizhi oral liquid its preparation method
CN104546823B (en) Epimedium aglucone treats or prevents the purposes in decrease of platelet disease drug in preparation
CN104922143B (en) The composition and its preparation method and application of EGCG and chitosan oligosaccharide
CN103622981A (en) Compound glycyrrhizin oral liquid and preparation method thereof
CN103239507A (en) Medicinal composition capable of being rapidly disintegrated and dissolved in oral cavity and preparation method thereof
CN102579536A (en) Enteric Panax Notoginseng total saponin preparation and preparation method thereof
CN112294883B (en) Stomach-strengthening tablet medicinal preparation and preparation method thereof
CN104780907A (en) Medicinal lozenge based on ibuprofen sodium dihydrate
CN106420697A (en) Polymethoxylated flavone, composition and application of polymethoxylated flavone preparation in preventing or treating diabetes
CN105663152A (en) Application of triacetyl-3-hydroxyphenyl adenosine in preparing medicines for improving insulin resistance and related diseases
CN105997949B (en) A kind of bulleyaconitine A orodispersible film preparation and its preparation process
CN101301350A (en) Lamioplomis rotate extract oral freeze-dried tablet and preparation thereof
CN1785247B (en) Disintegrant tablets, and its prepn. method
CN101019837B (en) Ginnone ester dispersing table and its preparation method
CN104958295A (en) Compound medicine composition for treating anaphylactic rhinitis
WO2011123994A1 (en) Traditional chinese medicine composition for treating hyperglycemia and preparation method thereof
CN105687208B (en) Application of cycloastragenol in preparation of medicine for treating heart failure
CN104434860A (en) Ambroxol hydrochloride osmotic pump type pharmaceutical composition prepared by inclusion process
CN114796161B (en) Topiroxostat oral instant film agent and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: HEILONGJIANG BAITONG CHILDREN'S MEDICAL RESEARCH C

Free format text: FORMER OWNER: KANGYANG RUNHE (BEIJING) MEDICAL TECHNOLOGY CO., LTD.

Effective date: 20150215

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 102600 FENGTAI, BEIJING TO: 150025 HARBIN, HEILONGJIANG PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20150215

Address after: 150025 Heilongjiang city of Harbin province Shenyang Limin Development Zone, East Street Zhuhai people Lunanli biomedical research center of life medicine venture building, No. 315

Applicant after: HEILONGJIANG BAITONG CHILDREN'S MEDICINES RESEARCH CO., LTD.

Address before: 102600 Beijing city Fengtai District Lize Road No. 1 Building No. 9, No. 104 (Pacific enterprises centralized office)

Applicant before: Kang Yangrun and (Beijing) Medical Technology Co., Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140312